A citation-based method for searching scientific literature

Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore, Andrew J Armstrong, Thomas W Flaig, Aude Fléchon, Paul Mainwaring, Mark Fleming, John D Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S de Bono. N Engl J Med 2012
Times Cited: 3022



Tomasz M Beer, Andrew J Armstrong, Dana Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Christopher P Evans, Choung-Soo Kim, Go Kimura, Kurt Miller, Fred Saad, Anders S Bjartell, Michael Borre, Peter Mulders, Teuvo L Tammela, Teresa Parli, Suha Sari, Steve van Os, Ad Theeuwes, Bertrand Tombal. Eur Urol 2017
Times Cited: 207




List of shared articles



Times cited

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Anthony V Serritella, Daniel Shevrin, Elisabeth I Heath, James L Wade, Elia Martinez, Amanda Anderson, Joseph Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M Stadler,[...]. Clin Cancer Res 2022
6

Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Clement Chung, Karen Abboud. Am J Health Syst Pharm 2022
0

Low-Dose Enzalutamide in Metastatic Prostate Cancer-Longevity Over Conventional Survival Analysis.
Vincent Vinh-Hung, Olena Gorobets, Gilles Natchagande, Paul Sargos, Ming Yin, Nam P Nguyen, Claire Verschraegen, Edmund Folefac. Clin Genitourin Cancer 2022
0

Hormonal prostate cancer therapies and cardiovascular disease: a systematic review.
Vittore Cereda, Pina T Falbo, Gaia Manna, Alessandro Iannace, Antonello Menghi, Michela Corona, Diana Semenova, Leonardo Calò, Roberto Carnevale, Giacomo Frati,[...]. Heart Fail Rev 2022
5

A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.
Daniel Westaby, Maria de Los Dolores Fenor de La Maza, Alec Paschalis, Juan M Jimenez-Vacas, Jon Welti, Johann de Bono, Adam Sharp. Annu Rev Pharmacol Toxicol 2022
9

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
Martin R Stockler, Andrew J Martin, Ian D Davis, Haryana M Dhillon, Stephen D Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague,[...]. J Clin Oncol 2022
13

2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Miikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, Timo Marttila, Ray McDermott, Timo Joensuu, Ilari Lehtinen, Claes Ginman, Pirkko-Liisa Kellokumpu-Lehtinen. Acta Oncol 2022
0